Risk Breakdown
Financial Exposure
Governance
Double Materiality
Supply Chain
Material Risks
ESG Targets & Commitments
| Topic | Target / Metric | Status |
|---|---|---|
| Human Rights in Supply Chain | HR clauses in all contracts | Commitment |
AI Risk Summary
**Financial Risk Summary: Alembic Pharmaceuticals Limited** Alembic faces its most acute financial exposure through critical compliance gaps—the maximal 10.0/10 compliance risk score and ₹10–36 crore estimated remediation cost represent material operational and reputational liability. The company's missing Scope 1 and Scope 2 emissions data creates immediate SEBI BRSR Core Expansion non-compliance risk, with potential enforcement action and delisting consequences for a ₹6,033 crore revenue entity. EPR exposure (6.5/10 risk) compounds this if pharmaceutical packaging fall under extended producer responsibility rules, adding unquantified future liabilities. Given current Indian carbon credit pricing (₹600–900/tonne), failure to establish baseline emissions and compliance infrastructure now risks substantially higher future compliance costs and market access restrictions.
Source: ALEMBIC PHARMACEUTICALS LIMITED BRSR Filing, FY -. Derived from the company's own public disclosures. Not investment advice or a regulatory determination.